

# Long COVID in Elderly Patients: An Epidemiologic Exploration Using a Medicare Cohort

Kin Wah Fung, MD

Fitsum Baye, MS

Seo H Baik, PhD

Zhaonian Zheng, MS

Clement J McDonald, MD

Affiliation: Lister Hill National Center for Biomedical Communications, National Library of Medicine, National Institutes of Health

Corresponding author:

Kin Wah Fung

[kfung@mail.nih.gov](mailto:kfung@mail.nih.gov)

301-827-5001

8600 Rockville Pike, Bethesda, MD 20894

Word count: 4,534

## 1 **Abstract**

2 **Background:** Incidence of long COVID in the elderly is difficult to estimate and can be under-reported.

3 While long COVID is sometimes considered a novel disease, many viral or bacterial infections have been  
4 known to cause prolonged illnesses. We postulate that some influenza patients might develop residual  
5 symptoms that would satisfy the diagnostic criteria for long COVID, a condition we call “long Flu”. In this  
6 study, we estimate the incidence of long COVID and long Flu among Medicare patients using the World  
7 Health Organization (WHO) consensus definition. We compare the incidence, symptomatology, and  
8 healthcare utilization between long COVID and long Flu patients.

9

10 **Methods and Findings:** This is a cohort study of Medicare (the U.S. federal health insurance program)  
11 beneficiaries over 65. ICD-10-CM codes were used to capture COVID-19, influenza and residual  
12 symptoms. Long COVID was identified by a) the designated long COVID-19 code B94.8 (code-based  
13 definition), or b) any of 11 symptoms identified in the WHO definition (symptom-based definition), from  
14 one to 3 months post infection. A symptom would be excluded if it occurred in the year prior to  
15 infection. Long Flu was identified in influenza patients from the combined 2018 and 2019 Flu seasons by  
16 the same symptom-based definition for long COVID. Long COVID and long Flu were compared in four  
17 outcome measures: a) hospitalization (any cause), b) hospitalization (for long COVID symptom), c)  
18 emergency department (ED) visit (for long COVID symptom), and d) number of outpatient encounters  
19 (for long COVID symptom), adjusted for age, sex, race, region, Medicare-Medicaid dual eligibility status,  
20 prior-year hospitalization, and chronic comorbidities. Among 2,071,532 COVID-19 patients diagnosed  
21 between April 2020 and June 2021, symptom-based definition identified long COVID in 16.6%  
22 (246,154/1,479,183) and 29.2% (61,631/210,765) of outpatients and inpatients respectively. The  
23 designated code gave much lower estimates (outpatients 0.49% (7,213/1,479,183), inpatients 2.6%

24 (5,521/210,765)). Among 933,877 influenza patients, 17.0% (138,951/817,336) of outpatients and 24.6%  
25 (18,824/76,390) of inpatients fit the long Flu definition. Long COVID patients had higher incidence of  
26 dyspnea, fatigue, palpitations, loss of taste/smell and neurocognitive symptoms compared to long Flu.  
27 Long COVID outpatients were more likely to have any-cause hospitalization (31.9% (74,854/234,688) vs.  
28 26.8% (33,140/123,736), odds ratio 1.06 (95% CI 1.05-1.08,  $p < 0.001$ )), and more outpatient visits than  
29 long Flu outpatients (mean 2.9(SD 3.4) vs. 2.5(SD 2.7) visits, incidence rate ratio 1.09 (95% CI 1.08-1.10,  
30  $p < 0.001$ )). There were less ED visits in long COVID patients, probably because of reduction in ED usage  
31 during the pandemic. The main limitation of our study is that the diagnosis of long COVID in is not  
32 independently verified.

33

34 **Conclusions:** Relying on specific long COVID diagnostic codes results in significant under-reporting. We  
35 observed that about 30% of hospitalized COVID-19 patients developed long COVID. In a similar  
36 proportion of patients, long COVID-like symptoms (long Flu) can be observed after influenza, but there  
37 are notable differences in symptomatology between long COVID and long Flu. The impact of long COVID  
38 on healthcare utilization is higher than long Flu.

39

## 40 **Author summary**

### 41 **Why was this study done?**

- 42 • The quoted incidence of long COVID varies widely because of differences in definition and  
43 measurement method. Long COVID in the elderly is likely to be under-reported because they are  
44 less likely to respond to surveys, and symptoms may be confused with other chronic diseases.  
45 We describe a method of identifying long COVID in the elderly using a standard definition.
- 46 • Lingering ill health after infections is not limited to COVID-19. We postulate that some patients  
47 may fit the diagnostic criteria of long COVID after a bout of influenza. We call this condition  
48 “long Flu”. Comparing and contrasting long COVID and long Flu may shed light on the  
49 understanding of long COVID, a disease still shrouded in mystery.

### 50 **What did the researchers do and find?**

- 51 • We applied the World Health Organization consensus clinical definition to identify long COVID  
52 among 2 million Medicare patients who were diagnosed with COVID-19 between April 2020 and  
53 June 2021.
- 54 • We applied the symptom-based long COVID definition to almost 900,000 influenza patients  
55 during the 2018 and 2019 Flu seasons to identify long Flu.
- 56 • Long COVID occurred in 16.6% of outpatients and 29.2% of inpatients. The corresponding rates  
57 for long Flu were 17% and 24.6%. If one had relied solely on the designated diagnostic code to  
58 identify long COVID, the estimated rates of long COVID would be 0.5% and 2.6% among  
59 outpatients and inpatients, way below the reported rates in most studies.

- 60       • Despite the similar overall incidence rates, long COVID patients suffered more often from  
61       difficulty in breathing, fatigue, palpitations, loss of taste/smell, memory problems, cognitive  
62       impairment and sleep disturbance than long Flu patients.
- 63       • Long COVID patients were also more likely to be admitted to hospital and had more outpatient  
64       visits on average than long Flu patients.

65       **What do these findings mean?**

- 66       • The use of designated long COVID diagnostic codes alone is likely to result in gross under-  
67       reporting.
- 68       • A similar proportion of influenza patients suffer from a prolonged illness resembling long COVID,  
69       but there are notable differences in the incidence of individual symptoms between long COVID  
70       and long Flu.
- 71       • Long COVID is associated with higher level of healthcare utilization than long Flu. This means  
72       that long COVID is likely to have a bigger impact on the individual's health as well as on society  
73       as a whole.

74

75

76

77

78

79

80

81 **1. Introduction**

82 Most Coronavirus Disease 2019 (COVID-19) patients recover completely after an infection with the  
83 SARS-CoV-2 virus. However, a proportion suffer from persistent health issues after the acute phase of  
84 COVID-19 [1-7]. Various names have been used to describe this condition, including long COVID, long-  
85 haulers, long-term effects of COVID-19, post-COVID syndrome, chronic COVID syndrome, post-COVID  
86 conditions and post-acute sequelae SARS-CoV-2 infection (PASC). We shall use long COVID in this report.  
87 Symptoms reported by long COVID patients range from fatigue, dyspnea, loss of smell to “brain fog”.  
88 The incidence of long COVID varies widely between studies, the majority are between 10% to 30% [8-  
89 19]. According to one estimation, up to 23 million people in the U.S. may have developed long COVID as  
90 of February 2022 [20]. Another study estimated that at least 3-5 million U.S. adults have activity-limiting  
91 long COVID [21].

92 While it is known that elderly patients are more prone to develop severe COVID-19, some studies have  
93 identified age as a risk factor also for long COVID [22, 23]. So far, relatively few long COVID studies have  
94 focused on the elderly. Long COVID can be under reported in the elderly population because they may  
95 not be as troubled by, or ready to report, the symptoms as in younger people [24]. They may also be less  
96 likely to participate in Internet-based research or respond to questionnaires. Moreover, the long COVID  
97 symptoms may be masked by or attributed to existing chronic diseases. One study finds that almost a  
98 third of COVID-19 patients over 65 years developed one or more new or persistent clinical sequelae  
99 [25]. Another study reports significant deterioration in quality of life and functional decline in elderly  
100 patients 6 months after COVID-19 [26]. More information is needed to understand the impact of long  
101 COVID on the elderly population.

102 While long COVID is sometimes considered a novel disease, it is hardly a totally unexpected  
103 phenomenon. Many viral or bacterial infections have been known to cause prolonged illnesses in a

104 subset of patients [27]. Rheumatic fever following infection by *Streptococcus pyogenes* is a well-known  
105 example. Herpesviruses and enteroviruses are implicated in the cause of myalgic  
106 encephalomyelitis/chronic fatigue syndrome (ME/CFS), characterized by fatigue, musculoskeletal pain  
107 and post-exertional malaise [28]. First reports of prolonged symptoms after contracting Russian  
108 influenza dated back to the 19<sup>th</sup> century [10, 29]. More recently, the Severe Acute Respiratory Syndrome  
109 Coronavirus (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have  
110 been associated with post-acute phase persistent symptoms that affected approximately one-third of  
111 patients [30].

112 There are a lot of similarities between COVID-19 and influenza. Both diseases are caused by easily  
113 transmissible single-stranded RNA viruses primarily affecting the respiratory tract, with significant  
114 systemic manifestations. Both diseases affect millions of patients every year, presenting substantial  
115 medical and socioeconomic challenges. It is conceivable that, in some patients, a persistent state of ill  
116 health, similar to long COVID, can occur after influenza [31]. Given the similarities between COVID-19  
117 and influenza, we postulate that there is considerable overlap in the symptomatology of the post-viral  
118 syndromes that they are associated with. This means that some patients suffering from post-flu  
119 syndrome might meet the diagnostic criteria for long COVID, had the primary infection been COVID-19  
120 instead of influenza. For lack of a better name, we shall call this condition “long Flu”. Conceptually, long  
121 Flu patients can serve as an “influenza comparator group” for long COVID. We think that comparing long  
122 COVID and long Flu would bring new insights to the understanding of long COVID.

123 In this study, we develop a pragmatic algorithm to identify long COVID patients based on the clinical  
124 definition proposed by the World Health Organization (WHO). Furthermore, we apply the same  
125 algorithm to identify patients who may be suffering from long Flu in two previous influenza seasons  
126 (2018 and 2019) and compare them with long COVID patients in three aspects: incidence,  
127 symptomatology, and impact on healthcare utilization.

128

## 129 **2. Materials and methods**

### 130 **2.1 Study population**

131 The primary cohort of this study was all Medicare patients over 65 diagnosed to have COVID-19  
132 between April 2020 and June 2021. A control cohort of non-COVID-19 patients was identified by 1 to 5  
133 matching for the same period. An influenza comparator cohort was identified from two pre-pandemic  
134 influenza seasons in 2018 and 2019. Through the Virtual Research Data Center (VRDC) [32] of the  
135 Centers for Medicare and Medicaid Services (CMS), we accessed de-identified encounter data of all  
136 Medicare beneficiaries from 2016-2021. Medicare is the U.S. federal government's health insurance  
137 program that primarily covers people 65 and older, and certain younger people with disabilities or  
138 kidney failure. Most individuals become eligible for Medicare when they reach 65 [33]. By one estimate,  
139 almost all (93%) of non-institutionalized persons 65 and over, about 52 million in 2017, are covered by  
140 Medicare [34]. We focused our analysis only on Medicare beneficiaries aged  $\geq 65$ , since younger  
141 Medicare beneficiaries are not representative of the general population aged  $< 65$  as they need  
142 qualifying disability conditions to enroll. To ensure we have sufficient data for symptom look-up (see  
143 below for method to identify long COVID and long Flu), we excluded patients a) with less than one year  
144 of Medicare coverage, b) with no encounters in a year prior to COVID-19 or influenza diagnosis, c) who  
145 were continuously enrolled in Medicare Advantage plans, mostly private health maintenance  
146 organization (HMO) plans that are not original Medicare fee-for-service (FFS) plans in the period  
147 between 1 year before and 12 weeks after the COVID-19 or influenza diagnosis. The last exclusion is  
148 necessary because Medicare claims data are potentially incomplete for patients enrolled in non-FFS  
149 plans. This study was declared not human subject research by the Office of Human Research Protection  
150 at the National Institutes of Health and by the CMS's Privacy Board. There was no prospective analysis  
151 protocol submitted before the commencement of this study.

## 152 2.2 Identifying long COVID and long Flu

### 153 2.2.1 Long COVID

154 We identified COVID-19 patients based on the International Classification of Disease-10<sup>th</sup> Version-Clinical  
155 Modification (ICD-10-CM) code *U07.1 COVID-19*, in either inpatient or outpatient claims between April  
156 1, 2020, and June 30, 2021. We stopped at June 2021 to ensure that we have acquired complete data  
157 for long COVID analysis because of several months' lag for claim maturity. We separated COVID-19  
158 patients into two mutually exclusive groups: outpatient and inpatient. For outpatients, the first COVID-  
159 19 diagnosis must be an outpatient coding, and the patient must not be admitted to an inpatient facility  
160 (acute care hospital or skilled nursing facility (SNF)) for COVID-19 within 4 weeks of COVID-19 diagnosis.  
161 A SNF is an in-patient rehabilitation and medical treatment center which provides a wide range of  
162 medical care including physical therapy, intravenous therapy, injections, monitoring of vital signs and  
163 medical equipment. For Inpatients, a) the first COVID-19 diagnosis must be an inpatient coding, or b) the  
164 first COVID-19 diagnosis is an outpatient coding, but the patient must be admitted to an inpatient facility  
165 for COVID-19 within 4 weeks of the COVID-19 diagnosis.

166 For identification of long COVID, we tried two approaches. The first was based on the recommended  
167 ICD-10-CM code for long COVID, *B94.8 Sequelae of other specified infectious and parasitic diseases*,  
168 during our study period (**code-based definition**). B94.8 can potentially be used in non-COVID-19  
169 infections, but significant use of this code in Medicare data occurred only after April 2020 (usage  
170 increased over 20-fold), making it reasonably specific for long COVID. Note that after our study, a new  
171 specific code for long COVID, *U09.9 Post COVID-19 condition*, became available from October 2021.  
172 During peer review of this paper, additional analysis was suggested to study the impact of the new long  
173 COVID code on the diagnosis of long COVID. This was done using additional data from September to  
174 December 2021 which had become available after our study was concluded. The second approach was

175 based on a constellation of symptoms (**symptom-based definition**). We followed the WHO’s clinical  
176 definition that was developed through a consensus process involving over 200 experts, researchers and  
177 patients [35]:

178 *“Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-*  
179 *CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at*  
180 *least 2 months and cannot be explained by an alternative diagnosis. Common symptoms*  
181 *include fatigue, shortness of breath, cognitive dysfunction but also others which generally have*  
182 *an impact on everyday functioning. Symptoms may be new onset, following initial recovery*  
183 *from an acute COVID-19 episode, or persist from the initial illness. Symptoms may also fluctuate*  
184 *or relapse over time.”*

185 We used ICD-10-CM codes to identify the 11 symptoms that at least 50% of the participants in the  
186 WHO’s consensus building process thought were critical to include (see S1 Table for their incidence and  
187 temporal trend). Long COVID was defined as presence of any of the 11 symptoms unless they were  
188 excluded (see below for exclusion criteria). We also did a sensitivity analysis using only the top 3  
189 symptoms (fatigue, shortness of breath, cognitive dysfunction) that reached 70% agreement in the  
190 WHO’s consensus building. For outpatients, we looked for symptoms from 4 to 12 weeks after the  
191 COVID-19 diagnosis. For inpatients, we started looking for long COVID symptoms after they were  
192 discharged to their original place of residence, following the recommendation from Amenta et al [36].  
193 The observation period for inpatients was from 2 to 10 weeks after discharge to compensate for the  
194 median hospitalization period of 2 weeks.

195 We did not include SNF patients (9% of all COVID-19 patients) in the inpatient group because the  
196 proportion of COVID-19 patients admitted to SNF was unusually high (32.6%) compared to influenza  
197 patients in two previous Flu seasons (4.2%). More importantly, 88.6% of SNF COVID-19 patients were

198 not discharged home but transferred to different inpatient facilities at the end of our study period. Two  
199 CMS policy changes in response to the pandemic may explain these phenomena: a) waiving of the three-  
200 day requirement of prior hospital stay for admission to SNF, and b) the extension of SNF coverage for an  
201 additional 100 days [37]. Since our identification of long COVID for inpatients started after their  
202 discharge, most of SNF patients did not satisfy the inclusion criteria.

203 To satisfy the requirement that “[the symptom] cannot be explained by an alternative diagnosis”, we  
204 tried two approaches:

205 1. **Exclusion by history** – the long COVID symptom must not be present from 2 weeks to 1 year  
206 before the COVID-19 diagnosis. We started the look-back period 2 weeks prior to COVID-19  
207 diagnosis because COVID-19-related symptoms started to increase from 2 weeks before the  
208 COVID-19 diagnosis, indicating a lag in diagnosis reporting (see S1 Table). Note that this  
209 exclusion only applied to individual symptoms, not to the patient as a whole. For example, if a  
210 patient had dyspnea 6 weeks after COVID-19 diagnosis, but the patient also complained of  
211 dyspnea 6 months before COVID-19 diagnosis, then dyspnea would not be counted as a long  
212 COVID symptom. However, the patient was not excluded and might still be identified as long  
213 COVID due to other symptoms.

214 2. **Exclusion by history and comorbidities** – in addition to 1 above, we excluded symptoms that  
215 could be explained by a known comorbidity, e.g., dyspnea excluded in the presence of chronic  
216 obstructive pulmonary disease (see S2 Table for excluded symptoms). We used the chronic  
217 condition onset dates in the Medicare database to identify comorbidities [38].

218 To estimate the false positive rate of the symptom-based definition, we matched each outpatient  
219 COVID-19 case to 5 controls (never had the code *U07.1 COVID-19* or *Z86.16 Personal history of COVID-*  
220 *19*) on age in years, race, sex, dual-eligibility status (a surrogate for income), geographic region and

221 Charlson comorbidity index [39] (within a range of +/- 2). We applied the same symptom-based  
222 definition on controls to assess the proportion of patients who would be falsely identified as long COVID.

### 223 **2.2.2 Long Flu**

224 Since the incidence of influenza diminished significantly during the COVID pandemic, we used data from  
225 two pre-pandemic Flu seasons, October 2017 – May 2018 (2018 season) and October 2018 – May 2019  
226 (2019 season) to estimate the incidence of the postulated long Flu. We identified influenza patients  
227 using the ICD-10-CM codes J09, J10 and J11. Similar to COVID-19, we separated influenza patients into  
228 outpatient and inpatient groups. We used the same list of long COVID symptoms and symptom  
229 exclusion criteria to identify long Flu. The observation period was the same as for long COVID, i.e., from  
230 4 to 12 weeks after influenza diagnosis for outpatients, and 2 to 10 weeks after discharge for inpatients.  
231 We excluded all SNF influenza inpatients (0.5% of total) from the long Flu cohort to be comparable with  
232 the long COVID cohort.

### 233 **2.3 Comparing long COVID and long Flu**

234 We compared the incidence and the distribution of symptoms between long COVID and long Flu  
235 patients. To estimate the impact of long COVID or long Flu on healthcare utilization, we analyzed four  
236 outcomes: a) hospitalization (any cause), b) hospitalization (due to any long COVID symptom), c)  
237 emergency department (ED) visit (due to any long COVID symptom), and d) number of outpatient  
238 (excluding ED) encounters (due to any long COVID symptom). We ran analyses of each of four outcomes  
239 separately for outpatients and hospitalized patients. For outpatients, we observed the outcomes for the  
240 period 4-12 weeks post COVID-19 or influenza diagnosis. For inpatients, the observation period was 2-10  
241 weeks post discharge.

### 242 **2.4 Statistical analysis**

243 We included all patients with COVID-19 or influenza, including those diagnosed with both. When we had  
244 to compare COVID-19 and influenza patients statistically, we excluded patients who had both conditions  
245 to ensure independence between groups. To test the difference in incidence of each specific symptom  
246 between long COVID and long Flu patients, we first implemented a two-by-two contingency Chi-square  
247 test [40], and used Hochberg method to control for familywise error rate from multiple hypotheses  
248 testing by decreasing the number of false positives [41]. We then used a multiple logistic regression  
249 model [42] to compare them further controlling for age, sex, race, region, dual eligibility and Charlson  
250 comorbidity index and reported the adjusted odds ratios. We did not have to deal with missing data as  
251 demographics and socioeconomic data were always present.

252 To test the difference in the first three outcomes of healthcare utilization (hospitalization any cause,  
253 hospitalization with long COVID symptoms, ED visit with long COVID symptoms), we implemented a  
254 generalized linear model with logit link adjusting for all available patient characteristics (age, sex, race,  
255 geographical region, dual eligibility status, history of any hospitalization in prior year, and 55 chronic  
256 conditions) as covariates. We adjusted for these covariates because demographics, comorbidities and  
257 socioeconomic factors are known to affect healthcare utilization. To compare the number of outpatient  
258 visits with long COVID symptoms, we used a generalized linear model with a log link function (i.e.,  
259 Poisson regression or log-linear regression analysis) with the same set of covariates as adjusters. We  
260 used the generalized estimating equations (GEE) method to account for overdispersion in the Poisson  
261 regression model.

262  
263 The primary goal of this study is to estimate the incidence of long COVID in the elderly by various  
264 approaches (code-based and symptom-based). Furthermore, we aim to compare the incidence,  
265 symptomatology, and healthcare utilization of long COVID with the hypothetical condition of long Flu.

266 This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology  
267 (STROBE) guideline (S1 Checklist).

268

### 269 **3. Results**

#### 270 **3.1 Patient characteristics**

271 We began with 2,434,154 COVID-19, 1,033,515 influenza and 8,755,799 control Medicare beneficiaries  
272 aged  $\geq 65$ . After applying exclusion criteria discussed in 2.1., we were left with 2,071,532 COVID-19  
273 patients of whom 1,479,183 (71.4%) were outpatients (Fig 1). We combined data from the two Flu  
274 seasons (2018 and 2019) because they were quite similar in terms of patients' health status and  
275 demographics (see S3 Table). There were 933,877 influenza patients of whom 817,336 (87.5%) were  
276 outpatients. All cases and controls were followed-up for 2 months to identify long COVID or long Flu,  
277 making a total follow-up time of 1.5 million patient years.

278

279 Fig 1 Participant inclusion, exclusion, and matching

280

281 Table 1 shows the characteristics of the COVID-19 and influenza patients. Note that in comparing two  
282 groups, 91,796 COVID-19 patients who also had influenza in previous two Flu seasons were excluded  
283 (3% of total). Among the hospitalized patients, influenza patients were older and sicker (higher prior  
284 hospitalization rate and Charlson comorbidity index) than COVID-19 patients, but the difference was  
285 much smaller among outpatients.

286

287

288

	Outpatient			Inpatient (hospitalized)		
	COVID-19	Influenza <sup>a</sup>	P value <sup>b</sup>	COVID-19	Influenza <sup>a</sup>	P value <sup>b</sup>
N (%)	1,479,183 (100)	817,336 (100)		399,124 (100)	111,721 (100)	
Any prior hospitalization <sup>c</sup>	349,688(23.6)	174,024(21.3)	<.0001	121,372(30.4)	42,868(38.4)	<.0001
CCI, mean±SD	1.9±2.3	1.9±2.2	<.0001	2.6±2.6	3.0±2.6	<.0001
Age, median (IQR)	75.0(70.0-82.0)	74.0(70.0-81.0)	<.0001	78.0(72.0-85.0)	81.0(74.0-88.0)	<.0001
65-69	313,613(21.2)	185,573(22.7)	<.0001	58,643(14.7)	11,826(10.6)	<.0001
70-74	389,872(26.4)	225,954(27.6)	<.0001	86,543(21.7)	18,726(16.8)	<.0001
75-79	277,075(18.7)	160,188(19.6)	<.0001	79,671(20.0)	20,232(18.1)	<.0001
80-84	205,435(13.9)	110,568(13.5)	<.0001	70,961(17.8)	20,733(18.6)	<.0001
85+	293,188(19.8)	135,053(16.5)	<.0001	103,306(25.9)	40,204(36.0)	<.0001
Female	853,157(57.7)	491,113(60.1)	<.0001	201,712(50.5)	65,020(58.2)	<.0001
Race: White	1,165,494(78.8)	664,540(81.3)	<.0001	296,000(74.2)	92,339(82.7)	<.0001
Black	117,273(7.9)	55,488(6.8)	<.0001	46,349(11.6)	8,637(7.7)	<.0001
Hispanic	111,488(7.5)	50,594(6.2)	<.0001	34,782(8.7)	6,176(5.5)	<.0001
Asian	37,698(2.5)	24,401(3.0)	<.0001	9,870(2.5)	2,448(2.2)	<.0001
Other	47,230(3.2)	22,313(2.7)	<.0001	12,123(3.0)	2,121(1.9)	<.0001
Region: Northeast	322,838(21.8)	131,762(16.1)	<.0001	76,301(19.1)	22,251(19.9)	<.0001
Midwest	309,689(20.9)	160,077(19.6)	<.0001	97,444(24.4)	30,757(27.5)	<.0001
South	566,699(38.3)	384,311(47.0)	<.0001	164,849(41.3)	38,622(34.6)	<.0001
West	265,878(18.0)	129,759(15.9)	<.0001	57,326(14.4)	18,873(16.9)	<.0001
Income: Ever Dual	367,459(24.8)	156,074(19.1)	<.0001	108,094(27.1)	28,562(25.6)	<.0001
Non-Dual LIS	21,666(1.5)	14,397(1.8)	<.0001	8,806(2.2)	2,466(2.2)	<.0001
Non-Dual Non-LIS	1,090,058(73.7)	646,865(79.1)	<.0001	282,224(70.7)	80,693(72.2)	<.0001

289 Table 1. Characteristics of COVID-19 and influenza patients (CCI – Charlson comorbidity index, SD –  
 290 standard deviation, IQR – inter-quartile range, LIS – low-income subsidy)

291 <sup>a</sup> combined 2018 & 2019 Flu seasons

292 <sup>b</sup> excluding 91,796 patients with both COVID-19 and influenza

293 <sup>c</sup> any prior hospitalization within one year of COVID-19 or influenza diagnosis

294

295 Each COVID-19 outpatient was matched to 5 non-COVID-19 patients. Overall, there were 6,286,633

296 controls with unmatched rate (COVID-19 patients unable to be matched) of 1.1% . The cases and

297 controls were generally quite well matched in terms of demographics and Charlson comorbidity index -.

298 Due to the large sample size, most differences between cases and controls were statistically significant

299 but the absolute standardized difference <0.25 indicated good balance between them (S4 Table) [43].

### 300 3.2 Incidence of long COVID and long Flu

301 Among the hospitalized COVID-19 and influenza patients, 52.8% (210,765/399,124) and 68.4%  
 302 (76,390/111,721) respectively were discharged to their original place of residence by the end of our  
 303 study period. These patients were used to estimate the incidence of long COVID and long Flu in  
 304 inpatients. Based on the ICD-10-CM diagnosis code of B94.8 (i.e., the code-based definition), only 0.49%  
 305 of outpatients and 2.6% of hospitalized patients were identified to develop long COVID (Table 2), way  
 306 lower than most published reports. Using the symptom-based definition, the estimated incidence of  
 307 long COVID was closest to other studies when we applied the definition of “any of 11 symptoms with  
 308 history exclusion only”. By this definition, the incidence of long COVID was 16.6% and 29.2% in  
 309 outpatients and hospitalized patients respectively. If we added the comorbidity exclusion to this  
 310 definition, the rates would drop to 5.7% (outpatient) and 8.8% (inpatient). We shall use the “any of 11  
 311 symptoms with history exclusion only” definition as our main result in subsequent discussion.

Long COVID definition	Outpatient		Inpatient (hospitalized)		Control
	COVID-19	Influenza	COVID-19	Influenza	Matched with COVID-19 outpatient
N(%)	1,479,183(100)	817,336(100)	210,765(100)	76,390(100)	6,286,633(100)
Code-based (B94.8)	7,213(0.49)	39(<0.01)	5,521(2.6)	11(0.01)	264 (<0.01)
Symptom-based					
Any of 11 symptoms with history exclusion only	246,154(16.6)	138,951(17.0)	61,631(29.2)	18,824(24.6)	658,229(10.5)
Any of 11 symptoms with history and comorbidity exclusion	84,774(5.7)	50,616(6.2)	18,486(8.8)	4,804(6.3)	220,751(3.5)
Any of 3 main symptoms with history exclusion only	142,175(9.6)	70,680(8.7)	42,690(20.3)	10,907(14.3)	357,915(5.7)
Any of 3 main symptoms with history and comorbidity exclusion	54,754(3.7)	30,053(3.7)	13,531(6.4)	3,302(4.3)	148,251(2.4)

312 Table 2. Incidence of long COVID and long Flu by various definitions

313

### 314 3.3 Difference in symptomatology of long COVID and long Flu

315 After excluding 91,796 patients with both COVID-19 and influenza (3% of all COVID-19 and influenza  
 316 patients), we had 293,172 long COVID patients (outpatient 234,688, inpatient 58,484) and 140,697 long  
 317 Flu patients (outpatient 123,736, inpatient 16,961) (Table 3). Rates of dyspnea, fatigue, palpitations, and  
 318 loss of taste/smell were significantly higher in long COVID than long Flu, among both outpatients and  
 319 hospitalized patients. In contrast, cough, chest pain, headache, and muscle/joint pain were more  
 320 frequent in long Flu in both outpatient and inpatient groups. The incidence of memory problem,  
 321 cognitive impairment and sleep disturbance were significantly higher in long COVID among outpatients  
 322 only.

Symptoms	Long COVID (%)	Long Flu (%)	P value <sup>a</sup>	Adjusted OR (95% CI) <sup>b</sup>
<b>Outpatient</b>	N=234,688(100)	N=123,736(100)		
dyspnea	66,562(28)	29,689(24)	<0.001	1.25(1.23,1.27)
fatigue/malaise/weakness	76,881(33)	36,547(30)	<0.001	1.15(1.13,1.16)
cough	45,776(20)	32,192(26)	<0.001	0.69(0.67,0.70)
chest pain	41,697(18)	22,538(18)	0.002	0.97(0.95,0.99)
palpitations	31,120(13)	13,940(11)	<0.001	1.20(1.18,1.23)
headache	17,950(8)	10,637(9)	<0.001	0.89(0.87,0.91)
muscle/ joint pain	14,097(6)	8,332(7)	<0.001	0.91(0.88,0.93)
memory problem	8,261(4)	4,097(3)	0.002	1.09(1.05,1.13)
cognitive impairment	6,698(3)	2,671(2)	<0.001	1.29(1.23,1.35)
sleep disturbance	2,360(1)	1,148(0.9)	0.024	1.10(1.02,1.18)
loss of taste/smell	1,537(0.7)	414(0.3)	<0.001	2.02(1.81,2.26)
<b>Inpatient (hospitalized)</b>	N=58,484(100)	N=16,961(100)		
dyspnea	24,915(43)	5,186(31)	<0.001	1.51(1.45,1.57)
fatigue/malaise/weakness	20,500(35)	5,424(32)	<0.001	1.25(1.21,1.30)
cough	11,425(20)	4,247(25)	<0.001	0.69(0.66,0.72)
chest pain	9,773(17)	3,065(18)	<0.001	0.91(0.87,0.95)
palpitations	8,467(14)	2,054(12)	<0.001	1.22(1.15,1.28)
headache	3,026(5)	1,288(8)	<0.001	0.71(0.66,0.76)
muscle/ joint pain	2,103(4)	715(4)	<0.001	0.86(0.79,0.94)
memory problem	1,849(3)	648(4)	0.034	0.91(0.83,1.00)
cognitive impairment	1,066(2)	401(2)	<0.001	0.89(0.79,1.01)
sleep disturbance	508(0.9)	137(0.8)	0.448	1.09(0.90,1.33)
loss of taste/smell	288(0.5)	42(0.3)	<0.001	2.04(1.47,2.83)

323 Table 3. Symptoms in long COVID and long Flu patients (OR – odds ratio of developing each specific  
 324 symptom for long COVID compared to long Flu, CI – confidence interval)

325 <sup>a</sup> adjusted for multiple hypothesis testing from Chi-Square test

326 <sup>b</sup> adjusted for age, sex, race, region, dual eligibility and Charlson comorbidity index

327

328 **3.4 Difference in healthcare utilization in long COVID and long Flu**

329 For both outpatients and hospitalized patients, long COVID was associated with significantly higher  
 330 chance of any hospitalizations and more outpatient visits than long Flu (Table 4). The difference is  
 331 especially notable among hospitalized patients, even though hospitalized influenza patients, at the  
 332 baseline, were sicker and older than hospitalized COVID-19 patients, which should normally translate  
 333 into more healthcare utilization. In contrast, the likelihood of an ED visit was significantly higher among  
 334 long Flu patients.

	Healthcare utilization			
	Any hospitalization (%)	Symptom-specific <sup>a</sup> hospitalization (%)	Symptom-specific <sup>a</sup> ED visit (%)	Number of symptom-specific <sup>a</sup> outpatient visits, mean (SD)
Outpatient				
Long COVID, N=234,688	74,854(31.9)	36,721(15.6)	25,131(10.7)	2.9(3.4)
Long Flu, N=123,736	33,140(26.8)	16,065(13.0)	15,566 (12.6)	2.5(2.7)
Inpatient (hospitalized)				
Long COVID, N=58,484	20,182(34.5)	8,286(14.2)	7,816(13.4)	2.9(3.2)
Long Flu, N=16,961	6,245(36.8)	2,593(15.3)	2,749(16.2)	2.8(3.0)
Comparative risk of long COVID patients relative to long Flu patients <sup>b</sup>	<b>OR (95%CI, p value)</b>	<b>OR (95%CI, p value)</b>	<b>OR (95%CI, p value)</b>	<b>IRR (95%CI, p value)</b>
Outpatient	1.06(1.05,1.08, <0.001)	1.00(0.98,1.02, 0.979)	0.80(0.78,0.82, <0.001)	1.09(1.08,1.10, <0.001)
Inpatient (hospitalized)	1.24(1.19,1.29, <0.001)	1.20(1.14,1.27, <0.001)	0.90(0.86,0.95, <0.001)	1.09(1.07,1.11, <0.001)

335 Table 4. Healthcare utilization of long COVID and long Flu patients (ED – emergency department, SD –  
 336 standard deviation, OR – odds ratio, IRR – incidence rate ratio, CI – confidence interval)

337 <sup>a</sup> with any of the 11 symptoms of long COVID

338 <sup>b</sup> adjusted for age, sex, race, geographical region, dual eligibility status, history of any hospitalization in prior year, and chronic comorbidities

339

340

341 **4. Discussion**

342 One major hurdle in long COVID-19 research is the difficulty in identifying long COVID cases. Due to the  
 343 wide range of definitions, the results of studies often cannot be compared or generalized [12]. The  
 344 development of a consensus on clinical definition by the WHO partially fills this gap [35]. Our study has

345 developed a method to operationalize this clinical definition. The WHO definition depends on the  
346 presence of a constellation of symptoms but requires that the symptoms do not have an alternative  
347 explanation. Identifying such explanations can be done in observational studies. We compared two  
348 approaches – exclusion by history (the symptom did not occur within the previous year) and exclusion  
349 by history and comorbidities. The use of exclusion by history alone yields estimates of long COVID of  
350 16.6% in outpatients and 29.2% in hospitalized patients, which are close to many published results. A  
351 recent large meta-analysis covering 194 studies shows that on average, at least 45% of COVID-19  
352 survivors (non-hospitalized patients 34.5%, hospitalized patients 52.6%) continue to experience at least  
353 one unresolved symptom [44]. This means that our results are likely to be an under-estimation. One  
354 potential problem of exclusion of individual symptoms based on history is that common symptoms are  
355 more likely to be excluded, even if they are indeed related to long COVID. In our study, the incidence of  
356 cognitive impairment and memory problem among long COVID patients is lower than that reported in  
357 the literature [44]. Since these problems are generally more common among elderly patients, they are  
358 more likely to be excluded by coincidence. Another factor that can be at play is that the threshold of  
359 seeking help for these problems may be higher in elderly patients. Adding the exclusion based on  
360 comorbidities cuts the estimates significantly to 5.7% for outpatients and 8.8% for hospitalized patients.  
361 We speculate that the comorbidity exclusion is probably too strict because some comorbidities are very  
362 prevalent in our study population of elderly Medicare beneficiaries. For example, high prevalence of  
363 heart failure (43%), chronic obstructive pulmonary disease (41%), and fibromyalgia chronic pain and  
364 fatigue (54%) would lead to exclusion of cough, dyspnea, and fatigue.

365 A recent study shows promise in the use of machine learning to identify long COVID [45]. However, the  
366 model in Pfaff et al. was only built on a very small, 0.6%, subset of 97,995 COVID-19 patients attending a  
367 long COVID clinic, highlighting the difficulty of identifying *all* patients suffering from long COVID. For  
368 machine learning methods to be effective, a large number of cases along with high-quality data is

369 required. Achieving this goal can be difficult because long COVID tends to be under-reported and under-  
370 coded [46]. In our study, code-based identification of long COVID yields an estimation of only 0.49% in  
371 outpatients and 2.6% in hospitalized patients, way below published results. A specific long COVID code,  
372 U09.9, was delivered in October 2021, however, healthcare providers were slow to take advantage of  
373 this code [47]. Based on additional data from September to December 2021, which became available  
374 after our study concluded, we found that the new long COVID code (U09.9) was used more often than  
375 the old one (B94.8), whose usage dropped off significantly. Using the new code in our code-based  
376 definition, 2.0% (11,424/573,965) of outpatients and 9.2% (6,253/68,030) of hospitalized patients  
377 developed long COVID. This is still considerably lower than most reports in the literature. Researchers  
378 should be aware of the potential under-reporting if they rely solely on specific codes to identify long  
379 COVID.

380 We postulate the existence of “long Flu” based on reports of post-infectious sequelae after influenza  
381 [29]. Long COVID has attracted special attention because of the pandemic, but the possible occurrence  
382 of prolonged symptoms from influenza should not be overlooked. Long COVID is still a poorly  
383 understood disease. Comparing and contrasting long COVID with long Flu may offer new insights into its  
384 pathogenesis and treatment. The pathogenesis of long COVID is likely to be complex and more than one  
385 mechanism may be implicated in some clinical manifestations [28, 48]. Evidence suggests that prolonged  
386 inflammation probably plays a key role. In addition, it is known that, like other coronaviruses, SARS-CoV-  
387 2 can invade the blood-brain barrier and access the central nervous system through peripheral or  
388 olfactory neurons [49, 50]. This could explain the greater incidence of psychoneurological symptoms  
389 (e.g., cognitive impairment, loss of taste or smell, memory problem and sleep disturbance) in long  
390 COVID compared to long Flu in our study. Another special feature of COVID-19 is the high incidence of  
391 thromboembolism, probably as a result of endothelial injury and heightened inflammation, which can  
392 lead to organ or tissue injury [51, 52]. Investigators have found high incidence of significant radiological

393 and functional abnormalities indicative of lung parenchymal and small airway disease after the acute  
394 phase of COVID-19, which could give rise to dyspnea and easy fatigue [53].

395 Based on our estimation, the incidence of long COVID and long Flu is comparable among outpatients  
396 (16.6% vs. 17.0%), and slightly higher for long COVID in inpatients (29.2% vs. 24.6%). But incidence alone  
397 doesn't tell the whole story about the impact of the two diseases. Our model on healthcare utilization  
398 shows that long COVID patients are more likely to seek outpatient care and be hospitalized, after  
399 controlling for demographics, socioeconomic factors, and comorbidities. This suggests that long COVID is  
400 a more serious illness than long Flu and has greater societal impact. One unexpected finding is the  
401 reduced ED visits in long COVID patients. This is probably an anomaly and could be explained by the fact  
402 that overall, ED visits shrunk during the pandemic, possibly because patients fearing exposure to COVID-  
403 19 avoided the ED for conditions for which they otherwise would have sought emergency care. Long flu  
404 data came from 2017-2019, and we observed that the overall usage of ED dropped by 18% in 2020  
405 compared with 2017-2019 among Medicare senior beneficiaries.

406 We recognize the following limitations. Based on our exclusion criteria, 15% of COVID-19 patients, 10%  
407 of influenza patients and 28% of matched controls were excluded, which may affect the generalizability  
408 of our findings. Not all COVID-19 diagnoses are captured in Medicare claims data. Our previous study  
409 showed that up to one-third of COVID-19 cases could be missed [54]. Medicare claims-based data may  
410 miss services or treatment paid for by private insurance or other means. The code-based definition of  
411 long COVID is based on the recommended code available for the study period, which may not be specific  
412 for long COVID. The symptom-based definition relies on the symptoms reported as "diagnosis" at the  
413 healthcare encounter and may not be sensitive because providers may not routinely code all symptoms.  
414 Using claims data, we cannot easily ascertain the duration of the symptoms as stipulated in the WHO  
415 definition. There is no independent confirmation that patients identified by our method are indeed  
416 suffering from long COVID. However, we can venture some estimation of our error rates. False positive

417 rate can be estimated by the positive rate in controls (10.5%). Among the 12,734 patients specifically  
418 coded as long COVID (code-based definition), 8,239 (64.7%) patients were identified as long COVID by  
419 the symptom-based definition, so the false negative rate can be estimated to be about 35%. If we adjust  
420 our results by these estimated error rates, the incidence of long COVID would be 9% for outpatients and  
421 28% for inpatients, still not far from other studies. Our observation period ends at 12 weeks after the  
422 COVID-19 or influenza diagnosis. Some patients may present with long COVID or long Flu after that  
423 period. Among the inpatients, we exclude SNF patients because a significant proportion of them are not  
424 discharged within the study period. We assume that long Flu is similar to long COVID and use the same  
425 symptomatic definition. There may be symptoms in post-influenza syndrome that are not common in  
426 long COVID, and patients with those symptoms may not be identified as long Flu in our study.

427 Based on a constellation of symptoms identified in the WHO's consensus definition, we estimate that  
428 long COVID occurs in 16.6% and 29.2% of elderly COVID-19 outpatients and inpatients respectively. The  
429 corresponding incidence for long Flu, identified by the same constellation of symptoms for two pre-  
430 pandemic influenza seasons, is about the same (17% and 24.6%). Long COVID patients have significantly  
431 higher incidence of dyspnea, fatigue, palpitations, loss of taste or smell, and neurocognitive symptoms.  
432 Compared to long Flu, patients with long COVID are hospitalized more often and have more outpatient  
433 visits, suggesting that it is a more serious illness and has higher societal impact.

434

435

436

437

438

439

440

## 441 References

- 442 1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.  
443 *Nature*. 2021;594(7862):259-64. Epub 2021/04/23. doi: 10.1038/s41586-021-03553-9. PubMed PMID:  
444 33887749.
- 445 2. Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. *JAMA*.  
446 2020;324(17):1723-4. Epub 2020/10/09. doi: 10.1001/jama.2020.19719. PubMed PMID: 33031513;  
447 PubMed Central PMCID: PMC8019677.
- 448 3. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in  
449 patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-32. Epub 2021/01/12.  
450 doi: 10.1016/S0140-6736(20)32656-8. PubMed PMID: 33428867; PubMed Central PMCID:  
451 PMC87833295.
- 452 4. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric  
453 outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health  
454 records. *Lancet Psychiatry*. 2021;8(5):416-27. Epub 2021/04/10. doi: 10.1016/S2215-0366(21)00084-5.  
455 PubMed PMID: 33836148; PubMed Central PMCID: PMC8023694 no competing interests.
- 456 5. Wanga V, Chevinsky JR, Dimitrov LV, Gerdes ME, Whitfield GP, Bonacci RA, et al. Long-Term  
457 Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. *MMWR Morb*  
458 *Mortal Wkly Rep*. 2021;70(36):1235-41. Epub 2021/09/10. doi: 10.15585/mmwr.mm7036a1. PubMed  
459 PMID: 34499626; PubMed Central PMCID: PMC8437054 Journal Editors form for disclosure of  
460 potential conflicts of interest. No potential conflicts of interest were disclosed.
- 461 6. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al.  
462 More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep*.  
463 2021;11(1):16144. Epub 2021/08/11. doi: 10.1038/s41598-021-95565-8. PubMed PMID: 34373540;  
464 PubMed Central PMCID: PMC8352980.
- 465 7. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After  
466 Acute COVID-19. *JAMA*. 2020;324(6):603-5. Epub 2020/07/10. doi: 10.1001/jama.2020.12603. PubMed  
467 PMID: 32644129; PubMed Central PMCID: PMC807349096.
- 468 8. Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms,  
469 and criteria adopted for long COVID-19: A systematic review. *Int J Clin Pract*. 2021;75(10):e14357. Epub  
470 2021/05/13. doi: 10.1111/ijcp.14357. PubMed PMID: 33977626; PubMed Central PMCID:  
471 PMC8236920.
- 472 9. Ahmad MS, Shaik RA, Ahmad RK, Yusuf M, Khan M, Almutairi AB, et al. "LONG COVID": an  
473 insight. *Eur Rev Med Pharmacol Sci*. 2021;25(17):5561-77. Epub 2021/09/18. doi:  
474 10.26355/eurrev\_202109\_26669. PubMed PMID: 34533807.
- 475 10. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID,  
476 a comprehensive systematic scoping review. *Infection*. 2021;49(6):1163-86. Epub 2021/07/29. doi:  
477 10.1007/s15010-021-01666-x. PubMed PMID: 34319569; PubMed Central PMCID: PMC8317481.
- 478 11. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term  
479 Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Netw Open*.  
480 2021;4(10):e2128568. Epub 2021/10/14. doi: 10.1001/jamanetworkopen.2021.28568. PubMed PMID:  
481 34643720; PubMed Central PMCID: PMC8515212.
- 482 12. Rando HM, Bennett TD, Byrd JB, Bramante C, Callahan TJ, Chute CG, et al. Challenges in defining  
483 Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported  
484 information. *medRxiv*. 2021. Epub 2021/04/02. doi: 10.1101/2021.03.20.21253896. PubMed PMID:  
485 33791733; PubMed Central PMCID: PMC8010765.
- 486 13. Huang Y, Pinto MD, Borelli JL, Mehrabadi MA, Abrihim H, Dutt N, et al. COVID Symptoms,  
487 Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the


- 488 Pandemic. medRxiv. 2021. Epub 2021/03/11. doi: 10.1101/2021.03.03.21252086. PubMed PMID:  
489 33688670; PubMed Central PMCID: PMC7941647.
- 490 14. Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-  
491 Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA.  
492 2021;325(15):1525-34. Epub 2021/03/18. doi: 10.1001/jama.2021.3331. PubMed PMID: 33729425;  
493 PubMed Central PMCID: PMC7970386.
- 494 15. Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, et al. Population-Based  
495 Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
496 Infection (PASC) Prevalence and Characteristics. Clin Infect Dis. 2021;73(11):2055-64. Epub 2021/05/20.  
497 doi: 10.1093/cid/ciab408. PubMed PMID: 34007978; PubMed Central PMCID: PMC8240848.
- 498 16. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, et al. Post-acute effects of SARS-  
499 CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.  
500 Lancet Infect Dis. 2021;21(10):1373-82. Epub 2021/05/14. doi: 10.1016/S1473-3099(21)00211-5.  
501 PubMed PMID: 33984263; PubMed Central PMCID: PMC8110209 participation in research projects  
502 funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, and LEO  
503 Pharma, outside the the current work. LCL reports funds paid to his institution for participation in  
504 research projects funded by Menarini Pharmaceuticals and LEO Pharma, outside the current work. HN  
505 reports funds paid to their institution for participation in research projects funded by Merck Sharp &  
506 Dohme and Novo Nordisk Foundation, outside the current work. The institution of CFC and RWT is  
507 involved in studies with funding from various companies as research grants to (and administered by)  
508 Aarhus University, outside the current work. AK, SHM, and NCB report no competing interests.
- 509 17. Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-Acute Sequelae of SARS-  
510 CoV-2 Infection Among Adults Aged  $\geq 18$  Years - Long Beach, California, April 1-December 10, 2020.  
511 MMWR Morb Mortal Wkly Rep. 2021;70(37):1274-7. Epub 2021/09/17. doi:  
512 10.15585/mmwr.mm7037a2. PubMed PMID: 34529639; PubMed Central PMCID: PMC8445372  
513 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest  
514 were disclosed.
- 515 18. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in  
516 Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2):e210830. Epub 2021/02/20.  
517 doi: 10.1001/jamanetworkopen.2021.0830. PubMed PMID: 33606031; PubMed Central PMCID:  
518 PMC7896197.
- 519 19. UK Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-  
520 19) infection in the UK. Sept 2021 dataset. Available from:  
521 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/  
522 datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk).
- 523 20. U.S. Government Accountability Office. Science & Tech Spotlight: Long COVID. Available from:  
524 [https://www.gao.gov/products/gao-22-  
525 105666?utm\\_source=onepager&utm\\_medium=email&utm\\_campaign=email\\_staa](https://www.gao.gov/products/gao-22-105666?utm_source=onepager&utm_medium=email&utm_campaign=email_staa).
- 526 21. Tenforde MW, Devine OJ, Reese HE, Silk BJ, Iuliano AD, Threlkel R, et al. Point Prevalence  
527 Estimates of Activity-Limiting Long-Term Symptoms among U.S. Adults  $\geq 1$  Month After Reported  
528 SARS-CoV-2 Infection, November 1, 2021. J Infect Dis. 2022. Epub 2022/07/02. doi:  
529 10.1093/infdis/jiac281. PubMed PMID: 35776165; PubMed Central PMCID: PMC9278232.
- 530 22. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and  
531 predictors of long COVID. Nat Med. 2021;27(4):626-31. Epub 2021/03/12. doi: 10.1038/s41591-021-  
532 01292-y. PubMed PMID: 33692530; PubMed Central PMCID: PMC7611399.
- 533 23. Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al. Long-COVID: An  
534 evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10-2. Epub 2021/01/07. doi:  
535 10.7196/SAMJ.2020.v111i11.15433. PubMed PMID: 33403997.

- 536 24. Graham J. 'That's Just Part of Aging': Long Covid Symptoms Are Often Overlooked in Seniors.  
537 Kaiser Health News. Available from: <https://khn.org/news/article/long-covid-symptoms-seniors/>.
- 538 25. Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, et al. Risk of persistent and new  
539 clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2  
540 infection: retrospective cohort study. *BMJ*. 2022;376:e068414. Epub 2022/02/11. doi: 10.1136/bmj-  
541 2021-068414. PubMed PMID: 35140117; PubMed Central PMCID: PMC8828141 at  
542 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: support from Optum Laboratories for the submitted  
543 work; no financial relationships with any organizations that might have an interest in the submitted  
544 work in the previous three years; no other relationships or activities that could appear to have  
545 influenced the submitted work. KC declares consulting from Pfizer. ML declares honoraria/consulting  
546 from Merck, Sanofi-Pasteur, Bristol Myers-Squibb, and Antigen Discovery; research funding  
547 (institutional) from Pfizer; and unpaid scientific advisory services to Janssen, Astra-Zeneca, One Day  
548 Sooner, and Covaxx (United Biomedical).
- 549 26. Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related  
550 quality of life, functional decline, and long-term mortality in older patients following hospitalisation due  
551 to COVID-19. *BMC Geriatr*. 2021;21(1):199. Epub 2021/03/24. doi: 10.1186/s12877-021-02140-x.  
552 PubMed PMID: 33752614; PubMed Central PMCID: PMC83098.
- 553 27. Bannister BA. Post-infectious disease syndrome. *Postgrad Med J*. 1988;64(753):559-67. Epub  
554 1988/07/01. doi: 10.1136/pgmj.64.753.559. PubMed PMID: 3074289; PubMed Central PMCID:  
555 PMC82428896.
- 556 28. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview  
557 of Biological Factors That May Contribute to Persistent Symptoms. *Front Microbiol*. 2021;12:698169.  
558 Epub 2021/07/13. doi: 10.3389/fmicb.2021.698169. PubMed PMID: 34248921; PubMed Central PMCID:  
559 PMC8260991.
- 560 29. Honigsbaum M, Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to  
561 COVID-19 long-haulers. *Lancet*. 2020;396(10260):1389-91. Epub 2020/10/16. doi: 10.1016/S0140-  
562 6736(20)32134-6. PubMed PMID: 33058777; PubMed Central PMCID: PMC827550169.
- 563 30. Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical  
564 outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome  
565 coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J*  
566 *Rehabil Med*. 2020;52(5):jrm00063. Epub 2020/05/26. doi: 10.2340/16501977-2694. PubMed PMID:  
567 32449782.
- 568 31. Chen J, Wu J, Hao S, Yang M, Lu X, Chen X, et al. Long term outcomes in survivors of epidemic  
569 Influenza A (H7N9) virus infection. *Sci Rep*. 2017;7(1):17275. Epub 2017/12/10. doi: 10.1038/s41598-  
570 017-17497-6. PubMed PMID: 29222500; PubMed Central PMCID: PMC825722861.
- 571 32. Research Data Assistance Center (ResDAC). CMS Virtual Research Data Center (VRDC). Available  
572 from: <https://www.resdac.org/cms-virtual-research-data-center-vrdc>.
- 573 33. Kaiser Family Foundation. A Primer on Medicare - Key facts about the Medicare program and  
574 the people it covers. Available from: [https://files.kff.org/attachment/report-a-primer-on-medicare-key-  
575 facts-about-the-medicare-program-and-the-people-it-covers](https://files.kff.org/attachment/report-a-primer-on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers).
- 576 34. Administration on Aging - U.S. Department of Health and Human Services. 2018 Profile of Older  
577 Americans. Available from: [https://acl.gov/aging-and-disability-in-america/data-and-research/profile-  
578 older-americans](https://acl.gov/aging-and-disability-in-america/data-and-research/profile-older-americans).
- 579 35. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi  
580 consensus. Available from: [http://www.fx1234.com/iris/bitstream/handle/10665/345824/WHO-2019-  
581 nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1&isAllowed=y](http://www.fx1234.com/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1&isAllowed=y).
- 582 36. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute  
583 COVID-19: An Overview and Approach to Classification. *Open Forum Infect Dis*. 2020;7(12):ofaa509.

- 584 Epub 2021/01/07. doi: 10.1093/ofid/ofaa509. PubMed PMID: 33403218; PubMed Central PMCID:  
585 PMC7665635.
- 586 37. Center for Medicare Advocacy. Expanded Medicare Skilled Nursing Facility Coverage During the  
587 Covid-19 Pandemic. Available from: <https://medicareadvocacy.org/snf-limitations-waived-during-covid/>.
- 588 38. Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse: CCW Chronic  
589 Condition Algorithms. . Available from: <https://www.ccwdata.org/web/guest/condition-categories>.
- 590 39. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The  
591 Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. *J Clin*  
592 *Epidemiol.* 2008;61(12):1234-40. Epub 2008/07/16. doi: 10.1016/j.jclinepi.2008.01.006. PubMed PMID:  
593 18619805.
- 594 40. Agresti A, Kateri M. *Categorical Data Analysis.* 2011. p. 206-8.
- 595 41. Chen S-Y, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. *Journal of*  
596 *Thoracic Disease.* 2017;9(6):1725-9.
- 597 42. Berkson J. Application of the Logistic Function to Bio-Assay. *Journal of the American Statistical*  
598 *Association.* 1944;39(227):357-65. doi: 10.2307/2280041.
- 599 43. Rubin DB. Using Propensity Scores to Help Design Observational Studies: Application to the  
600 Tobacco Litigation. *Health Services and Outcomes Research Methodology.* 2001;2(3):169-88. doi:  
601 10.1023/A:1020363010465.
- 602 44. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-  
603 term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic  
604 review and meta-analysis. *EClinicalMedicine.* 2023;55:101762. Epub 2022/12/08. doi:  
605 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID: PMC9714474.
- 606 45. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. Identifying who has long  
607 COVID in the USA: a machine learning approach using N3C data. *The Lancet Digital Health.*  
608 2022;4(7):e532-e41. doi: [https://doi.org/10.1016/S2589-7500\(22\)00048-6](https://doi.org/10.1016/S2589-7500(22)00048-6).
- 609 46. Walker AJ, MacKenna B, Inglesby P, Tomlinson L, Rentsch CT, Curtis HJ, et al. Clinical coding of  
610 long COVID in English primary care: a federated analysis of 58 million patient records *in situ*  
611 using OpenSAFELY. *British Journal of General Practice.* 2021;71(712):e806-e14. doi:  
612 10.3399/bjgp.2021.0301.
- 613 47. Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding Long COVID:  
614 Characterizing a new disease through an ICD-10 lens. *medRxiv.* 2022:2022.04.18.22273968. doi:  
615 10.1101/2022.04.18.22273968.
- 616 48. Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. *Vaccines*  
617 *(Basel).* 2021;9(5). Epub 2021/06/03. doi: 10.3390/vaccines9050497. PubMed PMID: 34066007; PubMed  
618 Central PMCID: PMC8151752.
- 619 49. Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-  
620 CoV-2 in human and mouse brain. *bioRxiv.* 2020:2020.06.25.169946. doi: 10.1101/2020.06.25.169946.
- 621 50. Ritchie K, Chan D, Watermeyer T. The cognitive consequences of the COVID-19 epidemic:  
622 collateral damage? *Brain Communications.* 2020;2(2). doi: 10.1093/braincomms/fcaa069.
- 623 51. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and  
624 Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and  
625 Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2020;75(23):2950-73. Epub 2020/04/21. doi:  
626 10.1016/j.jacc.2020.04.031. PubMed PMID: 32311448; PubMed Central PMCID: PMC7164881.
- 627 52. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid  
628 Antibodies in Patients with Covid-19. *N Engl J Med.* 2020;382(17):e38. Epub 2020/04/09. doi:  
629 10.1056/NEJMc2007575. PubMed PMID: 32268022; PubMed Central PMCID: PMC7161262.
- 630 53. Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux P-O, Brutsche M, Clarenbach C, et al.  
631 Pulmonary function and radiological features 4 months after COVID-19: first results from the national

632 prospective observational Swiss COVID-19 lung study. *European Respiratory Journal*.  
633 2021;57(4):2003690. doi: 10.1183/13993003.03690-2020.  
634 54. Fung KW, Baik SH, Baye F, Zheng Z, Huser V, McDonald CJ. Effect of common maintenance drugs  
635 on the risk and severity of COVID-19 in elderly patients. *PLoS One*. 2022;17(4):e0266922. Epub  
636 2022/04/19. doi: 10.1371/journal.pone.0266922. PubMed PMID: 35436293; PubMed Central PMCID:  
637 PMCPMC9015134.  
638

639	Supporting information
640	S1 Checklist Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
641	checklist
642	S1 Table Long COVID symptoms and temporal trends
643	S2 Table Exclusion of symptoms by comorbidities
644	S3 Table Patient characteristics in the 2018 and 2019 Flu seasons
645	S4 Table COVID-19 outpatient cases and controls
646	S5 Table Detailed statistical data of the logistic and Poisson regression models for healthcare utilization
647	
648	



medRxiv preprint doi: <https://doi.org/10.1101/2023.02.09.23285742>; this version posted February 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure